Phathom Pharmaceuticals Stock Analysis

Phathom Stock Analysis Notes

About 78.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.76. Phathom Pharmaceuticals had not issued any dividends in recent years. Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Phathom Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. To find out more about Phathom Pharmaceuticals contact Terrie Curran at 877 742 8466 or learn more at https://www.phathompharma.com.

Phathom Pharmaceuticals Investment Alerts

Phathom Largest EPS Surprises

View All Earnings Estimates

Phathom Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Phathom Stock Institutional Investors

Note, although Phathom Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Phathom Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 954.1 M.

Phathom Profitablity

The company has Profit Margin (PM) of (1.87) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.31) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.31.

Management Efficiency

Phathom Pharmaceuticals has return on total asset (ROA) of (0.4254) % which means that it has lost $0.4254 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (34.89) %, meaning that it created substantial loss on money invested by shareholders. Phathom Pharmaceuticals' management efficiency ratios could be used to measure how well Phathom Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 1.25 in 2026, whereas Return On Tangible Assets are likely to drop (0.84) in 2026. At this time, Phathom Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 659.5 M in 2026, whereas Liabilities And Stockholders Equity is likely to drop slightly above 267.1 M in 2026.

Technical Drivers

As of the 12th of February 2026, Phathom Pharmaceuticals holds the Risk Adjusted Performance of (0.01), variance of 14.68, and Coefficient Of Variation of (5,141). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Phathom Pharmaceuticals, as well as the relationship between them.

Phathom Pharmaceuticals Price Movement Analysis

Phathom Pharmaceuticals Insider Trading Activities

Phathom Pharmaceuticals Outstanding Bonds

Phathom Pharmaceuticals Predictive Daily Indicators

Phathom Pharmaceuticals Corporate Filings

Phathom Pharmaceuticals Forecast Models

Phathom Pharmaceuticals' time-series forecasting models are one of many Phathom Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Phathom Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Phathom Pharmaceuticals Bond Ratings

Phathom Pharmaceuticals financial ratings play a critical role in determining how much Phathom Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Phathom Pharmaceuticals' borrowing costs.

Phathom Pharmaceuticals Debt to Cash Allocation

Phathom Pharmaceuticals currently holds 554.95 M in liabilities with Debt to Equity (D/E) ratio of 2.43, implying the company greatly relies on financing operations through barrowing. Phathom Pharmaceuticals has a current ratio of 9.73, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Phathom Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Phathom Pharmaceuticals Total Assets Over Time

Phathom Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Phathom Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Phathom Pharmaceuticals Debt Ratio

177.0

It appears most of the Phathom Pharmaceuticals' assets are financed through debt. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Phathom Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Phathom Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Phathom Pharmaceuticals Corporate Bonds Issued

Phathom Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Phathom Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Phathom shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Phathom Pharmaceuticals. By using and applying Phathom Stock analysis, traders can create a robust methodology for identifying Phathom entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Phathom analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Phathom analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Phathom Pharmaceuticals stock analysis indicators help investors evaluate how Phathom Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Phathom Pharmaceuticals shares will generate the highest return on investment. By understating and applying Phathom Pharmaceuticals stock analysis, traders can identify Phathom Pharmaceuticals position entry and exit signals to maximize returns.

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.